| Species |
Human |
| Protein Construction |
| His |
Latexin (Glu2-Glu222)_x000D_
Accession # AAH05346 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit carboxypeptidase A1 cleavage of the colorimetric peptide substrate AcPheThiapheOH in the presence of 5,5'Dithiobis (2nitrobenzoic acid) (DTNB). The IC50 value is < 1 nM. Test result meets the standard. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
27.16 kDa |
| Apparent Molecular Weight |
The protein migrates to 30-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Latexin, the endogenous protein inhibitor of the A/B subfamily of metallocarboxypeptidases, is expressed in small nociceptive neurons in sensory ganglia and in a subset of neurons in the telencephalon. Recently, the latexin (Lxn) gene was identified as a potential tumor suppressor in several types of solid tumors and lymphoma, and Lxn expression was found to be absent or downregulated in leukemic cells. |
| Synonyms |
ECI; MUM; TCI; LXN |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
